Drugs / Twinrix

Trials 16 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00393276 Aug 2007 → Jul 2009 HIV infectious disease, hepatitis C virus infection National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00316303 Feb 2006 → Apr 2009 HIV infectious disease, bipolar disorder, depressive disorder, schizoaffective disorder +2 Dartmouth-Hitchcock Medical Center Completed No outcome recorded
Phase 2 NCT00107042 Feb 2004 → Jul 2008 hepatitis B virus infection University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 34 trials
Phase 3 NCT00465816 Apr 2007 → Apr 2008 meningococcal infection GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00451984 Mar 2007 → ? HIV infectious disease, hepatitis A virus infection, hepatitis B virus infection Aalborg University Hospital Unknown No outcome recorded
Phase 3 NCT00289770 Nov → Dec 2004 hepatitis A virus infection, hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00289718 Nov 2004 → Mar 2005 hepatitis A virus infection, hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded
Phase 48 trials
Phase 4 NCT01451801 Oct 2011 → Jul 2013 hepatitis B virus infection University of Aarhus Unknown No outcome recorded
Phase 4 NCT01126853 Apr 2010 → Jun 2011 hepatitis B virus infection Mount Sinai Hospital, Canada Withdrawn No outcome recorded
Phase 4 NCT00684671 May → Nov 2008 hepatitis A virus infection, hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT00603252 Jan → Jun 2008 hepatitis A virus infection, hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT00142753 Aug 2005 → Nov 2007 HIV infectious disease University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 4 NCT00186836 Nov 2004 → Nov 2006 hepatitis B virus infection St. Joseph's Health Care London Completed No outcome recorded
Phase 4 NCT00216229 Sep 2004 → Feb 2006 IDEWE Occupational Health Services Unknown No outcome recorded
Phase 4 NCT00289731 Nov 2003 → Dec 2004 hepatitis A virus infection, hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded
Phase not applicable1 trial
NCT00244374 Aug 2004 → Jun 2008 hepatitis A virus infection, hepatitis B virus infection, hepatitis C virus infection, substance abuse University of California, San Francisco Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02334462 Comparator Jan 2015 → Mar 2016 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 42 trials
Phase 4 NCT00106964 Comparator Jan 2004 → Jan 2008 HIV infectious disease, hepatitis B virus infection University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 4 NCT01259453 Comparator May 2003 → Aug 2006 hepatitis B virus infection Yale University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as Twinrix “who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.” NCT00289731
19

“At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine.” NCT00244374

“Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule” NCT01259453

NCT00316303

NCT00603252

NCT02334462

NCT00186836

NCT00451984

NCT00684671

NCT01126853

NCT00106964

NCT00142753

NCT00289718

NCT00107042

NCT00216229

NCT00289731

NCT00289770

NCT00393276

NCT00465816

NCT01451801

Known as Twinrix Adult Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.” NCT00465816
1

“Biological: Twinrix™ adult” NCT00289718

Known as Twinrix Junior “Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.” NCT00465816
Modality Vaccine “standard adult dosing of combined HBV/hepatitis A virus (HAV) vaccineNCT00106964
Route Intramuscular “A single dose of 1 mL will be administered in the deltoid muscle.” NCT00106964